

(19) World Intellectual Property
Organization
International Bureau



534584

(43) International Publication Date
3 June 2004 (03.06.2004)

PCT

(10) International Publication Number
WO 2004/046133 A1

(51) International Patent Classification⁷: **C07D 401/12**,
403/12, 401/14, 405/14, 471/04, A61K 31/4709, 31/4725,
A61P 29/00 // (C07D 471/04, 235:00, 221:00) (C07D
471/04, 249:00, 221:00)

(21) International Application Number:
PCT/GB2003/004969

(22) International Filing Date:
14 November 2003 (14.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0226724.3 15 November 2002 (15.11.2002) GB

(71) Applicant (for all designated States except US): **MERCK
SHARP & DOHME LIMITED** [GB/GB]; Hertford Road,
Hoddesdon, Hertfordshire EN11 9BU (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BLURTON, Peter**


[GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex
CM20 2QR (GB). **BURKAMP, Frank** [DE/GB]; Ter-
lings Park, Eastwick Road, Harlow, Essex CM20 2QR
(GB). **FLETCHER, Stephen, Robert** [GB/GB]; Terlings
Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).
HOLLINGWORTH, Gregory, John [GB/GB]; Terlings
Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).
JONES, A., Brian [GB/GB]; Terlings Park, Eastwick
Road, Harlow, Essex CM20 2QR (GB). **MCIVER, Ed-
ward, Giles** [GB/GB]; Terlings Park, Eastwick Road,
Harlow, Essex CM20 2QR (GB). **MOYES, Christopher,
Richard** [GB/GB]; Terlings Park, Eastwick Road, Harlow,
Essex CM20 2QR (GB). **ROGERS, Lauren** [GB/GB];
Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR
(GB).

(74) Agent: **HORGAN, James, Michael, Fred**; European
Patent Department, Terlings Park, Eastwick Road, Harlow,
Essex CM20 2QR (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR,

[Continued on next page]

(54) Title: AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN



(57) Abstract: the present invention provides a compound of formula (I): wherein V represents NR⁵, O, S, SO or S(O)₂; W and X each independently represent CH or N; Y represents N, CH or C-Ar₂, with the proviso that at least one, but no more than two, of W, X and Y are N; Z represents CH or C-Ar₂, with the proviso that when Y is N or CH then Z is C-Ar₂, and with the further proviso that when Y is C-Ar₂ then Z is CH; Ar₁ represents a fused 9 or 10 membered heterobicyclic ring system containing one, two, three or four heteroatoms selected from nitrogen, oxygen and sulfur, wherein at least one of the rings in said ring system is aromatic; Ar₂ represents an aromatic ring selected from phenyl, pyridyl, pyrimidinyl and pyridazinyl which is optionally fused and substituted; R¹ represents halogen, hydroxy, oxo, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, haloC₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkoxy, C₃₋₇cycloalkyl, C₃₋₇cycloalkoxy, C₃₋₇cycloalkylC₁₋₄alkyl, cyano, nitro, SR⁶, SOR⁶, SO₂R⁶, COR⁶, NR³COR⁶, CONR³R⁴, NR³SO₂R⁶, SO₂NR³R⁴, -(CH₂)_mcarboxy, esterified -(CH₂)_mcarboxy or -(CH₂)_mNR³R⁴; R² represents hydrogen, halogen, hydroxy, C₁₋₆alkyl, haloC₁₋₆alkyl, C₃₋₇cycloalkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, unsubstituted phenyl or phenyl substituted with one or two groups selected from halogen, C₁₋₆alkyl, haloC₁₋₆alkyl, C₃₋₇cycloalkyl, C₁₋₆alkoxy or haloC₁₋₆alkoxy; R³ and R⁴ are each independently hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₇cycloalkyl or fluoroC₁₋₆alkyl; or R³ and R⁴ and the nitrogen atom to which they are attached together form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C₁₋₄alkoxy, which ring may optionally contain as one of the said ring atoms an oxygen or a sulfur atom, S(O), S(O)₂, or NR⁵; R⁵ represents hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl or C₁₋₄alkoxyC₁₋₄alkyl; R⁶ represents hydrogen, C₁₋₆alkyl, fluoroC₁₋₆alkyl, C₃₋₇cycloalkyl, unsubstituted phenyl, or phenyl substituted with one or two groups selected from halogen, C₁₋₆alkyl, haloC₁₋₆alkyl, C₃₋₇cycloalkyl, C₁₋₆alkoxy or haloC₁₋₆alkoxy; m is either zero or an integer from 1 to 4; n is either zero or an integer from 1 to 3; or a pharmaceutically acceptable salt, N-oxide or a prodrug thereof; a pharmaceutical composition comprising it; its use in methods of treatment; use of it for the manufacture of a medicament for treating VR-1 related conditions such as those in which pain and/or inflammation predominate; and methods of treatment using it.

WO 2004/046133 A1